Showing results (221-230 of 239) with videos related to
Sort By:
Pageof 24
Practical Radiation Oncology|January 18, 2024
Systematic Implementation of Effective Quality Assurance Processes for the Assessment of Radiation Target Volumes in Head and Neck CancerE Gogineni, D Schaefer, A Ewing, et al.Journal of Medicinal Chemistry|October 5, 2001
Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitorsW Yao, Z R Wasserman, M Chao, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 28, 2007
Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humansMingxin Qian, Stephen A Bai, Bernice Brogdon, et al.Bioorganic & Medicinal Chemistry Letters|February 6, 2007
A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitorsXiao-Tao Chen, Bahman Ghavimi, Ronald L Corbett, et al.Bioorganic & Medicinal Chemistry Letters|March 27, 2003
Potent and selective aggrecanase inhibitors containing cyclic P1 substituentsRobert J Cherney, Ruowei Mo, Dayton T Meyer, et al.Bioorganic & Medicinal Chemistry Letters|December 3, 2003
Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimizationChu-Biao Xue, Xiaohua He, John Roderick, et al.Cellular Oncology (Dordrecht, Netherlands)|January 25, 2021
The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer modelsClara Lemos, Volker K Schulze, Simon J Baumgart, et al.Journal of Medicinal Chemistry|October 26, 2021
Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2ALars Wortmann, Nico Bräuer, Simon J Holton, et al.Current Topics in Medicinal Chemistry|April 8, 2011
G protein-coupled receptor transmembrane binding pockets and their applications in GPCR research and drug discovery: a surveyNicole A Kratochwil, Silvia Gatti-McArthur, Marius C Hoener, et al.Journal of Medicinal Chemistry|May 2, 2003
Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitorsRobert J Cherney, James J-W Duan, Matthew E Voss, et al.Pageof 24